About Us
Our Science
KatheraBio’s antifungal technology targets cellular enzymes that play an essential role in pathways regulating fungal growth and pathogenicity. Chemical genomic experiments indicate that the enzymes are also critically important for fungal cell wall biosynthesis and/or stress responses. We believe that targeting these cellular enzymes and pathways will lead to opportunities to develop innovative next generation antifungal monotherapies, or agents that can be used in combination therapies to synergistically treat infections caused by drug-resistant fungi. To learn more about our science, contact us.
Our Management Team
Stephen Parent PhD
Founder, Acting Board Member, Vice President, Business Strategy & Development
Our Consultants Advisory Board
Michael S. Cosgrove PhD
Structural Biologist, Biochemistry & Molecular Biology, Department, SUNY-Upstate Medical University